{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:47:57Z","timestamp":1792597677504,"version":"4.5.0"},"reference-count":7,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:p>This cross-sectional study examines changes in the prescribing of oral targeted therapy alongside the frequency of comanagement of advanced prostate cancer between urologists and medical oncologists.<\/jats:p>","DOI":"10.1001\/jamanetworkopen.2026.39853","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:00:35Z","timestamp":1792594835000},"page":"e2639853","source":"Crossref","is-referenced-by-count":0,"title":["Oral Targeted Therapies and Clinician Comanagement Among Men With Advanced Prostate Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Arnav","family":"Srivastava","sequence":"first","affiliation":[{"name":"Department of Urology, Emory University, Atlanta, Georgia"},{"name":"Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Sun","sequence":"additional","affiliation":[{"name":"Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan E. V.","family":"Caram","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahakn B.","family":"Shahinian","sequence":"additional","affiliation":[{"name":"Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent K.","family":"Hollenbeck","sequence":"additional","affiliation":[{"name":"Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"issue":"2","key":"zld260250r1","doi-asserted-by":"publisher","first-page":"e411","DOI":"10.1016\/j.clgc.2017.09.015","article-title":"Recognizing symptom burden in advanced prostate cancer: a global patient and caregiver survey.","volume":"16","author":"Drudge-Coates","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"zld260250r2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1089\/end.2011.0227","article-title":"Obstructive uropathy from locally advanced and metastatic prostate cancer: an old problem with new therapies.","volume":"26","author":"Friedlander","year":"2012","journal-title":"J Endourol"},{"issue":"11","key":"zld260250r3","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1093\/jnci\/djae155","article-title":"Adverse events in men with advanced prostate cancer treated with androgen biosynthesis inhibitors and androgen receptor inhibitors.","volume":"116","author":"Faraj","year":"2024","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"zld260250r4","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71475","article-title":"Impact of in-office dispensing adoption by urology practices on oral specialty drug use in advanced prostate cancer.","volume":"15","author":"Faraj","year":"2026","journal-title":"Cancer Med"},{"issue":"8","key":"zld260250r5","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/jnci\/djac081","article-title":"Risk of metabolic and cardiovascular adverse events with abiraterone or enzalutamide among men with advanced prostate cancer.","volume":"114","author":"Lai","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"zld260250r6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1056\/NEJMoa2510310","article-title":"Improved survival with enzalutamide in biochemically recurrent prostate cancer.","volume":"394","author":"Shore","year":"2026","journal-title":"N Engl J Med"},{"key":"zld260250r7","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.14694\/EdBook_AM.2015.35.e75","article-title":"Reform of the buy-and-bill system for outpatient chemotherapy care is inevitable: perspectives from an economist, a realpolitik, and an oncologist.","author":"Polite","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2855577\/srivastava_2026_ld_260250_1791995801.13118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:00:36Z","timestamp":1792594836000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2855577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":7,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.39853","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]}}}